The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


DICP, The Annals of Pharmacotherapy: Vol. 23, No. 10, pp. 40-43.
© 1989 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siepler, J.
Right arrow Articles by Petty, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Siepler, J.
Right arrow Articles by Petty, D.


Research Articles

Use of continuous infusion of histamine2-receptor antagonists in critically ill patients

JK Siepler, W Trudeau, and DE Petty

Certain clinical situations require the use of a histamine2 (H2)-receptor antagonist to reduce gastric-acid volume and concentration or an antacid to act as a buffering agent. Presently, there are three H2-receptor antagonists available for iv use: cimetidine, ranitidine, and famotidine. Conventional therapy dictates that the H2-receptor antagonist be given by intermittent intravenous infusion, resulting in peaks and valleys of acid secretory control. Antacids, although capable of providing adequate gastric acidity control, must be administered frequently, often hourly, and thus require excessive nursing time. Presented here is a review of the rationale for the use of an H2-receptor antagonist by continuous infusion.





homecopy help contact us subscription past issues search current issue
Copyright © 1989 by Harvey Whitney Books Company.